Both in Pharmaceuticals
Monopar Therapeutics vs Arvinas
Over the past year MNPR returned −16.8% and ARVN returned −27.1%; their daily moves had a correlation of 0.30.
MNPR −16.8% ARVN −27.1%Growth of $1, one year, split-adjusted
| Metric | MNPR | ARVN |
|---|---|---|
| Price | $69.89 | $7.09 |
| Market cap | $469.1M | $463.6M |
| Today | +5.45% | −5.72% |
| 1 month | −10.7% | −5.0% |
| 6 months | +22.9% | −33.2% |
| Year to date | +7.0% | −40.2% |
| 1 year | −18.9% | −30.1% |
| Revenue growth (YoY) | — | +1014.7% |
| Gross margin | — | 96.4% |
| Net margin | — | 67.8% |
| P/E (TTM) | — | 49.8× |
| Price / sales | — | 1.5× |
| Net cash | $134.3M | $567.6M |
| Dividend yield | — | — |
| Volatility (60d) | 51.7% | 48.4% |
| Short % of float | 23.3% | 10.2% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).